InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,214.08
(
0.51%
)
US TECH 100
17,644.00
(
0.24%
)
Dow Jones
39,387.76
(
0.85%
)
Brent Oil
83.95
(
0.46%
)
Bitcoin
62,569.84
(
2.26%
)
Post# of 1434
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Keep Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

rikic

Send PM Follow Ignore
Followers 2
Posts 298
Boards Moderated 0
Alias Born 08/16/2010

rikic

Re: None

Friday, 04/03/2015 2:09:06 AM

Friday, April 03, 2015 2:09:06 AM

Post# of 1434
Francisella Tularensis Infections - Pipeline Review, H1 2015

This report provides comprehensive information on the therapeutic development for Francisella Tularensis Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. Companies Involved in Therapeutics Development are Aradigm Corporation, EpiVax, Inc., Evolva SA, Tetraphase Pharmaceuticals Inc. Complete report available at

http://www.rnrmarketresearch.com/francisella-tularensis-infections-pipeline-review-h1-2015-market-report.html
Public Reply Private Reply New Post
Keep Last Read
Keep Last Read Next 10 Report Keyboard Shortcuts
Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up